AN EXPLORATORY COST-EFFECTIVENESS ANALYSIS OF CANCER VACCINES IN COMBINATION WITH CURRENT IMMUNE CHECKPOINT INHIBITORS VS IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY: A CASE STUDY FOR V940 IN HIGH-RISK STAGE 3 MELANOMA IN THE US

被引：0
|
作者：
Mclean, A. [1 ]
van Hest, N. [1 ]
机构：
[1] Costello Med, Bristol, Sommerset, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE354
引用
收藏
页码：S124 / S124
页数：1
相关论文
共 4 条
  • [1] Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III macroscopic melanoma: A matched cohort study.
    Boekhout, Annelies H.
    Jozwiak, Katarzyna
    Rozeman, Elisa A.
    Janssen, Silvie H. M.
    van de Poll-Franse, Lonneke V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
    Kang, Shuo
    Wang, Xinchen
    Zhang, Yue
    Zhang, Boyuan
    Shang, Fangjian
    Guo, Wei
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [3] First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
    Yi, Lidan
    Zhou, Zhen
    Zeng, Xiaohui
    Tan, Chongqing
    Liu, Qiao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).
    Hirano, Katsuya
    Hata, Akito
    Yamanaka, Yuta
    Sumi, Toshiyuki
    Tamiya, Motohiro
    Sato, Yuki
    Oya, Yuko
    Hamai, Kosuke
    Katakami, Nobuyuki
    Iwasaki, Katsuhiko
    Uenishi, Tatsuhiro
    Kokubo, Kinya
    Igarashi, Ataru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1